88768-40-5

Cilazapril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor cilazaprilat. In vivo, cilazapril (0.1 mg/kg) inhibits plasma ACE activity and inhibits the angiotensin I-induced pressor response in anesthetized rats and cats. It decreases systolic blood pressure in spontaneously hypertensive rats when administered at a dose of 30 mg/kg. Cilazapril (10 mg/kg, p.o.) decreases blood pressure in volume-depleted renal hypertensive dogs. Formulations containing cilazapril have been used in the treatment of hypertension.

Off-White Solid

An ACE inhibitor. Hydrolyzed in vivo to the active diacid metabolite (Cilazaprilat). Antihypertensive

An ACE inhibitor. Hydrolyzed in vivo to the active diacid metabolite (Cilazaprilat). Antihypertensive.

ChEBI: Cilazapril is a pyridazinodiazepine resulting from the formal condensation of the carboxy group of cilazaprilat with ethanol. It is a drug used in the treatment of hypertension and heart failure. It has a role as a prodrug, an antihypertensive agent and an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor. It is an ethyl ester, a pyridazinodiazepine and a dicarboxylic acid monoester. It is functionally related to a Cilazaprilat.

Inhibace (Hoffmann-LaRoche).

[1] WATERFALL J. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.[J]. British journal of clinical pharmacology, 1989, 27 S2: 139S-150S. DOI: 10.1111/j.1365-2125.1989.tb03475.x